ProQR a new buy at BoA on RNA-editing platform

ProQR Therapeutics (PRQR) reported Q2 2026 results, including a net loss of €8.7M and first clinical validation of its Axiomer platform. The company raised $59.2M in June and expects cash to last through mid-2028. AX-0810 showed promising Phase 1 data, and AX-0811 data is due by year-end. PRQR shares are up 7.28% to $2.38.

ProQR Therapeutics N.V. (PRQR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ProQR Announces Second Quarter 2026 Operating and Financial Results · First clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or sci

Apple plans to unveil three new smart home devices on October 13, including an updated HomePod mini and Apple TV 4K with improved features, and a new smart home hub with a 6-inch display. The devices will support Siri AI and feature enhanced hardware, according to Bloomberg.

Eli Lilly (LLY) reported that Foundayo, a GLP-1 receptor agonist, reduced predicted 10-year type 2 diabetes risk by 45-57% and cardiovascular disease risk by 13-18% in a Phase 3 trial. The study involved 3,127 adults with obesity or overweight. Foundayo is FDA-approved for chronic weight management and is being studied for other metabolic conditions. LLY shares are currently trading at $1,150.94, down 0.70%.

Barclays forecasts Nvidia's (NVDA) hyperscaler revenue to reach 44% market share by 2027, with revenue estimates significantly higher than prior projections. The firm maintains an Overweight rating and $275 price target. Nvidia's GF Value suggests it is 42.9% undervalued, with a GF Score of 96/100. Insiders have sold $2.17B in shares over the past year, with no insider buying reported.

Citi analyst Ronald Josey claims Alphabet's Gemini 4 Argon model outperforms rivals, removing a key overhang on GOOGL shares. The model ranks first in 14 of 19 benchmarks, with potential benefits for Google Cloud, Search, and Workspace. Citi sets a $447 price target, implying 30% upside. Near-term risks include limited availability and capacity constraints.